Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temanogrel for microvascular obstruction after PCI
2020-000238-16Phase 2Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Microvascular obstruction (MVO) comparing Temanogrel with Placebo (2 arms). Primary endpoint: Change in index of microcirculatory resistance from baseline to post-PCI. Started Dec 2020; status: terminated.
02
Drugs
temanogrel
03
Conditions
Microvascular obstruction (MVO)
Beyond the preview
Go deeper on 2020-000238-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000238-16.